Immix Biopharma (IMMX) stock
IMMX's Quality Score was unchanged on Tue, Oct 6, at -1.
Follow IMMX's news. Pro members can get an alert when Immix Biopharma files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Holding it back
112.7% more shares than a year ago.
5 more reasons behind IMMX's -1, for Pro members
What's next for IMMX, and how long its cash lasts
From Immix Biopharma’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
Over 5 years
Dilution on the horizon
- Shelf registration (S-3, filed Jan 9, 2026)
- At-the-market share sales program (424B5, filed Mar 25, 2026)
Insiders
CEO Ilya M Rachman bought 746 shares on Dec 10, 2025.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 23 daysINOInovio Pharmaceuticals
INOINO-3107
- In 34 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 46 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why IMMX scores -1
PoorTrending up, 1 of 14 checks firingWhat the Quality Score means
- +2Long-term trend above a rising 200-day average
- +2Run-up 368% over 12 months
- Chart checks adds
- Profit subtracts
- Dilution subtracts
- Volatility subtracts
- Cash flow subtracts
What's next
Expected to report Fri Nov 6, after the close
What would turn IMMX's score around: 7 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
IMMX has 1 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1433.5
- MACD (12, 26, 9)Below signal
- 50-day average$11.65
- 200-day average$9.19
- ADX 1429.4
- Support$9.60
- Resistance$9.77
- Bollinger Bands (20, 2)Inside
- Volume0.7x
How IMMX ranks in Biotech
IMMX is #157 of 308 by Quality Score. The top three are shown with their scores, and more by name.
KNSA6/1419
ONC6/1418
EXEL6/1416
ICLROpen for its score
IMCROpen for its score
IMNMOpen for its score
IMUXOpen for its score
IMMX1/14-1
When does IMMX report earnings, and what happens after?
Expected to report Fri Nov 6, after the close (in 30 days). Not yet confirmed by the company.
About Immix Biopharma
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of IMMX's score, with the points and the reason
- All 14 checks on IMMX and on all 3,283 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on IMMX
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.